SAN DIEGO, June 14, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of compounded drug formulations, today announced CEO Mark L. Baum will present at the National Investment Banking Association (NIBA) conference, set for June 17-19 in New York City. The Imprimis presentation is scheduled for June 18 th.
About Imprimis Pharmaceuticals, Inc . Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through its exclusive strategic relationship with Professional Compounding Centers of America (PCCA), the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technologies, as well as proprietary drug formulations for new indications and market data obtained through PCCA, to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need utilizing the FDA 505(b)(2) regulatory pathway. Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes the Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/.
About NIBA The National Investment Banking Association (NIBA) is the only not-for-profit association for national, regional and independent broker dealers, investment banking firms, investment advisors, and related capital market service providers. Its member firms: are responsible for 90 percent of all IPO's under $20 million; have successfully completed more than 1,000 equity offerings; have raised over $10 billion in new capital for emerging growth companies; represent more than 8,800 registered representatives; have more than $76 billion in assets under management; and represent more than 60 key industry services. For more information, visit http://nibanet.org/.
Contact: Josh BergImprimis Pharmaceuticals, Inc.(858) 704 4041SOURCE Imprimis Pharmaceuticals, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts